Thierry Le Chevalier
Overview
Explore the profile of Thierry Le Chevalier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
5602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seymour L, Le Teuff G, Brambilla E, Shepherd F, Soria J, Kratzke R, et al.
Clin Lung Cancer
. 2018 Nov;
20(2):66-73.e6.
PMID: 30414783
Background: Complete resection of non-small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no...
2.
Collaud S, Provost B, Besse B, Fabre D, Le Chevalier T, Mercier O, et al.
J Surg Oncol
. 2018 Mar;
117(7):1570-1574.
PMID: 29573419
Background: Traditionally, treatment for stage IIIB (T4N2M0 and T1-4N3M0) NSCLC consists in definitive chemoradiation. Surgery is used only anecdotally. Here, we studied outcome for patients treated with multimodality including surgery....
3.
Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, et al.
ESMO Open
. 2018 Feb;
1(6):e000118.
PMID: 29435365
Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine...
4.
Lawler M, Banks I, Law K, Albreht T, Armand J, Barbacid M, et al.
ESMO Open
. 2017 Aug;
1(6):e000127.
PMID: 28848664
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to...
5.
de Montpreville V, Ghigna M, Lacroix L, Lemoine A, Besse B, Mercier O, et al.
Pathol Res Pract
. 2017 May;
213(7):793-798.
PMID: 28554746
Objectives: EGFR and KRAS genes are routinely tested in lung carcinomas with therapeutic implications. However the current testing methods require complex infrastructures and the delay for diagnosis remains often rather...
6.
Shepherd F, Lacas B, Le Teuff G, Hainaut P, Janne P, Pignon J, et al.
J Clin Oncol
. 2017 Apr;
35(18):2018-2027.
PMID: 28453411
Purpose Our previous work evaluated individual prognostic and predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC). In this analysis, we explore the prognostic and predictive roles...
7.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al.
Oncoimmunology
. 2016 May;
5(4):e1071008.
PMID: 27141373
Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-γ-free) in end-stage...
8.
Ma X, Le Teuff G, Lacas B, Tsao M, Graziano S, Pignon J, et al.
J Thorac Oncol
. 2016 Feb;
11(6):850-61.
PMID: 26899019
Introduction: Tumor protein p53 gene (TP53) mutations are common in stage I through III non-small cell lung cancer, but clinical trials have shown inconsistent results regarding their relationship to the...
9.
Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al.
J Clin Oncol
. 2016 Feb;
34(11):1223-30.
PMID: 26834066
Purpose: Tumor lymphocytic infiltration (TLI) has differing prognostic value among various cancers. The objective of this study was to assess the effect of TLI in lung cancer. Patients And Methods:...
10.
Fabre D, Fadel E, Mussot S, Kolb F, Leymarie N, Mercier O, et al.
Chin Clin Oncol
. 2016 Jan;
4(4):46.
PMID: 26730758
Surgical research has failed during fifty years to find an ideal substitute for the trachea after extended resection. All the prostheses could erode the adjacent structures or lead to infection...